MacroCure Company Profile (NASDAQ:MCUR)

Analyst Ratings

Consensus Ratings for MacroCure (NASDAQ:MCUR) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s)
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: $7.13 (362.66% upside)

Analysts' Ratings History for MacroCure (NASDAQ:MCUR)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Credit Suisse Group AGDowngradeNeutral -> Underperform$1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015Jefferies GroupLower Price TargetHold$1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/20/2015Oppenheimer Holdings Inc.DowngradeOutperform -> Market Perform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/20/2015Nomura Holdings Inc.DowngradeBuy -> Neutral$20.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2014Credit Agricole SAInitiated CoverageOutperform$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for MacroCure (NASDAQ:MCUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/16/2016        
11/17/2015Q3($0.36)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.37)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.38)($0.38)$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q414($0.32)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.31)($0.70)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MacroCure (NASDAQ:MCUR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for MacroCure (NASDAQ:MCUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MacroCure (NASDAQ:MCUR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for MacroCure (NASDAQ:MCUR)
DateHeadline
07/23/16 09:02 AMMacrocure Limited Ord (NASDAQ:MCUR) Sellers Increased By 32.18% Their Shorts - Press Telegraph
07/19/16 11:14 AMCredit Suisse Gives Macrocure (NASDAQ:MCUR) Lower Rating. What Is Next? - Consumer Eagle
07/18/16 05:16 PMCredit Suisse Downgrades Macrocure Ltd (MCUR) to Underperform - StreetInsider.com
07/18/16 05:33 AMMacrocure downgraded by Credit Suisse -
07/17/16 04:34 PMHow Analysts Rated Macrocure Ltd (NASDAQ:MCUR) Last Week? - Consumer Eagle
07/15/16 04:09 PMMacrocure Limited Ord (NASDAQ:MCUR) Sellers Increased By 7.83% Their Shorts - Consumer Eagle
07/14/16 05:21 PMMacrocure Ltd. (MCUR) Current Analyst Ratings - Fiscal Standard
06/27/16 05:01 PMMacrocure Limited Ord (NASDAQ:MCUR) Shorted Shares Increased 7.83% After Market Selling - Press Telegraph
06/26/16 09:46 AMAre Analysts Bullish Macrocure Ltd (NASDAQ:MCUR) After Last Week? - Press Telegraph
06/21/16 09:34 AMMacrocure Ltd (NASDAQ:MCUR): That’s How Our Premium Members Are up 40% In Just 2 Weeks
06/20/16 04:58 PMMacrocure Ltd (NASDAQ:MCUR): That's How Our Premium Members Are up 40% In Just 2 Weeks - Market News Call
06/10/16 05:21 PMTrading Overview of Two Stocks: LDR Holding Corporation (NASDAQ:LDRH) , MACROCURE LTD. (NASDAQ:MCUR) - Street Updates
06/03/16 05:31 PMWill You Buy These Stocks? - Macrocure Ltd. (NASDAQ:MCUR), Xylem Inc. (NYSE:XYL) - Beacon Chronicle
06/03/16 07:53 AMMacrocure Ltd. (MCUR) Updated Price Targets - FTSE News - Macrocure Ltd. (MCUR) Updated Price TargetsFTSE NewsMacrocure Ltd. has a 50 day moving average of 1.10 and a 200 day moving average of 1.13. The stock's market capitalization is 19.64M, it has a 52-week low of 0.75 and a 52-week high of 16.10. The share price of the company (MCUR) was up +4.55%, with ...Macrocure Limited Ord (NASDAQ:MCUR) Shorted Shares Increased 34.54% After Market SellingHNNall 2 news articles »
04/20/16 06:00 AMMacrocure Files Annual Report on Form 20-F for the Year Ended December 31, 2015 - [PR Newswire] - PETACH TIKVA, Israel, April 20, 2016 /PRNewswire/ -- Macrocure Ltd. (NASDAQ: MCUR) (" Macrocure " or the " Company "), a clinical-stage biotechnology company, announced today that it ...
04/11/16 07:23 AMMacrocure Announces Receipt of NASDAQ Minimum Bid Price Notification - [PR Newswire] - Macrocure Ltd. (MCUR), a clinical-stage biotechnology company, today announced that on April 7, 2016, Macrocure received a notice from NASDAQ regarding its non-compliance with the $1 per share minimum bid price requirement stated in NASDAQ Listing Rule 5450(a)(1). Macrocure has until October 4, 2016 to regain compliance with the minimum bid price requirement, which will require Macrocure's ordinary shares to achieve a closing market price of $1 or more for a minimum of 10 consecutive business days. If Macrocure fails to meet this requirement, its ordinary shares will become subject to delisting from the NASDAQ Global Market.
02/26/16 09:35 AMMacrocure Limited Ord (NASDAQ:MCUR) Sellers Increased By 0.3% Their Shorts - RiversideGazette.com - Macrocure Limited Ord (NASDAQ:MCUR) Sellers Increased By 0.3% Their ShortsRiversideGazette.comThe stock of Macrocure Limited Ord (NASDAQ:MCUR) registered an increase of 0.3% in short interest. MCUR's total short interest was 397,800 shares in February as published by FINRA. Its up 0.3% from 396,600 shares, reported previously. With 64,500 ...and more »
02/17/16 01:37 PMLatest Analysts Reports On Macrocure Ltd. (MCUR) - Risers & Fallers - Latest Analysts Reports On Macrocure Ltd. (MCUR)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Macrocure Ltd. (MCUR). The latest broker reports which have been released state 0 analysts have a rating of “buy”, 0 analysts “outperform”, 3 analysts “hold”, 0 analysts ...and more »
02/16/16 01:29 PMMacrocure Limited Ord (NASDAQ:MCUR) Short Interest Increased By 0.3% - fdanewsalert.com - Macrocure Limited Ord (NASDAQ:MCUR) Short Interest Increased By 0.3%fdanewsalert.comThe stock of Macrocure Limited Ord (NASDAQ:MCUR) registered an increase of 0.3% in short interest. MCUR's total short interest was 397,800 shares in February as published by FINRA. Its up 0.3% from 396,600 shares, reported previously. With 64,500 ...Latest Analysts Reports On Macrocure Ltd. (MCUR)Risers & Fallersall 2 news articles »
02/09/16 12:38 PMAre Analysts Bullish Macrocure Ltd (NASDAQ:MCUR) After Last Week? - Sonoran Weekly Review - Are Analysts Bullish Macrocure Ltd (NASDAQ:MCUR) After Last Week?Sonoran Weekly ReviewOut of 2 analysts covering Macrocure (NASDAQ:MCUR), 0 rate it “Buy”, 0 “Sell”, while 3 “Hold”. This means 0% are positive. Macrocure was the topic in 9 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Below is a list of ...
01/28/16 11:35 AMMACROCURE LTD. (NASDAQ:MCUR) Short Interest Update - The Daily Rover - MACROCURE LTD. (NASDAQ:MCUR) Short Interest UpdateThe Daily RoverMACROCURE LTD. (NASDAQ:MCUR) has seen a rise of 9,333 shares or 2.4% in the short interest. The remaining shorts are 5.9% of the total floated shares. The net short interest, as on January 15,2016, stood at 396,582 shares and the stocks days to cover ...
12/09/15 10:43 AMMacrocure Announces Annual General Meeting of Shareholders - [at noodls] - Macrocure Announces Annual General Meeting of Shareholders
12/08/15 12:07 PMMACROCURE LTD. Financials -
11/27/15 12:24 PMMacrocure Ltd. Reports Changes to Senior Management and the Board of Directors - [at noodls] - Macrocure Ltd. Reports Changes to Senior Management and the Board of Directors
11/25/15 03:18 PMBears Must Bear With Upward Drift -
11/25/15 09:40 AMGetting That Holiday Trading Feeling -
11/17/15 03:27 PMMacrocure Ltd. Reports Third Quarter 2015 Financial Results - [at noodls] - PETACH TIKVA, Israel, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. ('Macrocure' or the 'Company') (NASDAQ:MCUR), today provided a corporate update and reported financial results for the third quarter ...
11/17/15 03:11 PMMacroCure reports 3Q loss -
10/28/15 12:42 PMWhy Three Biotech Stocks Are Getting Pounded Alongside A Financial Stock Today -
10/27/15 05:29 PMMacrocure's cell therapy for wounds fails late study - [Reuters] - Israeli biotechnology company Macrocure Ltd said it would "analyze all strategic options" after its cell therapy for hard-to-treat wounds failed a late-stage U.S. study, pushing its shares down more than 50 percent after the bell. Macrocure's CureXcell, already in use in Israel, is a formulation of living human white blood cells activated to stimulate the healing and closure of wounds from the inside out. Macrocure said on Tuesday that the drug did not meet the main goal in patients with diabetic foot ulcers.
10/27/15 04:57 PMMacrocure Ltd. Announces Results for Phase III Clinical Trial of CureXcell® in Diabetic Foot Ulcers and Provides Corporate Update - [at noodls] - PETACH TIKVA, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. ('Macrocure' or the 'Company') (NASDAQ:MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform ...
10/27/15 04:41 PMMacrocure's lead drug fails late-stage study - [Reuters] - Israeli drug developer Macrocure Ltd said its lead drug failed a late-stage study in patients with diabetic foot ulcers. Macrocure's CureXcell is a formulation of living human white blood cells that have ...
09/21/15 08:40 AMMoving Average Crossover Alert: Macrocure (MCUR) -

Social

About MacroCure

MacroCure logoMacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is an advanced wound care (AWC) therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process. CureXcell is in two pivotal, Phase 3, double-blind clinical trials targeting an indication for the treatment of DFUs and VLUs. The Company holds product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MCUR
  • CUSIP:
Key Metrics:
  • Previous Close: $1.54
  • 50 Day Moving Average: $1.39
  • 200 Day Moving Average: $1.12
  • P/E Ratio: N/A
  • P/E Growth: -0.15
  • Market Cap: $26.30M
  • Beta: 0.59
  • Current Year EPS Consensus Estimate: $-0.3 EPS
  • Next Year EPS Consensus Estimate: $-0.17 EPS
Additional Links:
MacroCure (NASDAQ:MCUR) Chart for Monday, July, 25, 2016